Long-Term Outcome in Patients With Heart Failure Treated With Levothyroxine

An Observational Nationwide Cohort Study

Mette Nygaard Einfeldt; Anne-Marie Schjerning Olsen; Søren Lund Kristensen; Usman Khalid; Jens Faber; Christian Torp-Pedersen; Gunnar H Gislason; Christian Selmer


J Clin Endocrinol Metab. 2019;104(5):1725-1734. 

In This Article


In conclusion, our study found an association between L-T4 treatment in patients with HF and an increased risk of all-cause mortality, cardiovascular death, and MACE. The association was independent of whether the patients were treated with L-T4 before or after the HF diagnosis. The association between L-T4 treatment and MI depended on whether treatment was ongoing at the time of HF diagnosis (increased risk) or initiated afterward (reduced risk). A randomized controlled trial is warranted to evaluate the prognostic impact of thyroid dysfunction and thyroid hormone substitution in patients with HF.